Financial Contrast: Qualigen Therapeutics (NASDAQ:AIXC) vs. AngioSoma (OTCMKTS:SOAN)

Qualigen Therapeutics (NASDAQ:AIXC) and AngioSoma (OTCMKTS:SOAN) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations for Qualigen Therapeutics and AngioSoma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1	0	0	0	1.00
AngioSoma	0	0	0	0	0.00

Given AngioSoma’s higher possible upside, analysts clearly believe AngioSoma is more favorable than Qualigen Therapeutics.

Volatility and Risk

Qualigen Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, AngioSoma has a beta of -0.46, indicating that its share price is 146% less volatile than the S&P 500.

Earnings and Valuation

This table compares Qualigen Therapeutics and AngioSoma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$16.97 million	($6.47)	-0.21
AngioSoma	N/A	N/A	-$540,000.00	N/A	N/A

Profitability

This table compares Qualigen Therapeutics and AngioSoma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	-771.52%	-79.52%
AngioSoma	N/A	N/A	-1,245.34%

Institutional and Insider Ownership

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of AngioSoma shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Qualigen Therapeutics beats AngioSoma on 5 of the 8 factors compared between the two stocks.

About Qualigen Therapeutics

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

About AngioSoma

AngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.